Synlett 2015; 26(03): 275-284
DOI: 10.1055/s-0034-1379426
synpacts
© Georg Thieme Verlag Stuttgart · New York

Towards Tris(diimine)–Ruthenium(II) and Bis(quinoline)–Re(I)(CO)3 Complexes as Photoactivated Anticancer Drug Candidates

Tanmaya Joshi*
,
Gilles Gasser*
Further Information

Publication History

Received: 19 August 2014

Accepted after revision: 14 October 2014

Publication Date:
09 January 2015 (online)


Abstract

The clinical success of cisplatin continues to inspire the development of metal-based anticancer drug candidates. This article is meant to present the current state-of-the-art and science of ruthenium(II)- and rhenium(I)-based anticancer drug candidates born out of our work in this field. Our recent efforts to elicit photoactivation of intact (organo)metallic anticancer drug candidates as a promising way for commanding their activity within cancer cells are also briefly summarized.

1 Introduction

2 Ruthenium(II) Complexes

3 Rhenium(I) Complexes

4 Concluding Remarks